U.S. Telecom Services and Carriers Stock News

Epsilon Energy (EPSN) has just posted its FY 2025 numbers with third quarter revenue of about US$9.0 million and basic EPS of US$0.05, set against trailing twelve month revenue of US$45.7 million and EPS of US$0.27 that came alongside 11.2% earnings growth and a trailing net margin of 12.9% compared with 17% a year earlier. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 2024 to US$16.2 million in Q1 2025, then to US$9.0 million in Q3 2025. Quarterly EPS has...

In March 2026, MINISO Group Holding Limited issued earnings guidance for fiscal 2025, projecting revenue of about RMB 21.44 billion–RMB 21.45 billion, operating profit of roughly RMB 3.30 billion, adjusted operating profit of about RMB 3.67 billion, and profit of around RMB 1.32 billion–RMB 1.33 billion, driven by a richer product portfolio, stronger brand recognition, and broader, more efficient sales channels. An interesting twist is that, despite the projected revenue growth and higher...

BioStem Technologies (OTCPK:BSEM) appointed Jodi Ungrodt as a new member of its Board of Directors and Chair of the Audit Committee. The company completed the acquisition of BioTissue Holdings Inc.'s surgical and wound assets, including a national sales force. The transaction expands BioStem's commercial reach into hospital settings and broadens its product portfolio. BioStem Technologies, trading at $4.92, sits at an interesting point in its share price history, with a 25.9% return year to...

Biohaven announced it has completed enrollment in a Phase 2 proof-of-concept trial of taldefgrobep alfa, a myostatin-activin pathway inhibitor being tested as a self-administered, dose-ranging monotherapy for overweight and obesity across 20 U.S. sites, with topline data expected in the second half of 2026. The program is drawing attention because taldefgrobep alfa aims to deliver high-quality weight loss by reducing fat mass while preserving or increasing lean muscle, a profile that differs...

If you are wondering whether AMETEK at around US$215 per share looks expensive or offers value, it is helpful to separate price action from underlying worth. The stock has seen mixed moves recently, with a 1.2% gain over the last 7 days, a 7.0% decline over 30 days, and returns of 3.0% year to date, 22.5% over the past year, 54.4% over 3 years, and 74.2% over 5 years. These moves come alongside a steady stream of company updates and industry commentary that keep AMETEK on many investors'...

Relief rally puts Norwegian Cruise Line Holdings (NCLH) back in focus A broad relief rally in travel stocks, sparked by a delayed military strike in Iran and renewed diplomatic talks in the Middle East, pushed Norwegian Cruise Line Holdings (NCLH) sharply higher on Monday. With geopolitical risk briefly easing and cruise peers also gaining, investors are reassessing how headline driven moves might affect NCLH’s risk profile, recent returns and valuation against other consumer cyclical...

In recent days, Wells Fargo and Jefferies upgraded ONEOK, citing how geopolitical tensions and shifting global energy flows could benefit its U.S. midstream network, including assets such as the Eiger Express Pipeline expansion and the Bighorn processing plant. The upgrades highlight how ONEOK’s existing pipeline and processing footprint may gain importance as buyers seek more reliable natural gas and NGL supply routes amid global disruptions. Next, we’ll explore how this geopolitical-driven...

Zhihu (NYSE:ZH) has posted a mixed FY 2025 update, with Q3 revenue at C¥658.9 million and basic EPS of C¥0.58 loss per share, while trailing 12 month figures show revenue of C¥2.97 billion and basic EPS of C¥1.25. Over recent quarters, revenue has shifted from C¥933.8 million in Q2 2024 to C¥859.2 million in Q4 2024, then to C¥716.9 million in Q2 2025 and C¥658.9 million in Q3 2025. Net income moved from a C¥82.7 million loss in Q2 2024 to a C¥72.5 million profit in Q2 2025, before a C¥46.7...

Why Flywire is On Investors’ Radar Today Flywire (FLYW) has been drawing attention after a stretch where its share price showed a mix of gains over the past month and declines across the past 3 months and year to date. Investors are weighing how this recent trading pattern lines up with the company’s fundamentals and global payments footprint. See our latest analysis for Flywire. With the share price at $12.40, Flywire’s recent 16.5% 1 month share price return contrasts with its 14.3% 3 month...

Recent share performance and business snapshot W. R. Berkley (WRB) has seen recent share pressure, with the stock showing negative returns over the past week, month, and past 3 months. Its 1 year and multi year total returns remain positive. The commercial insurer reports revenue of US$14,707.856m and net income of US$1,779.403m. Annual revenue growth is 0.40% and net income growth is 2.62%, supported by operations across Insurance and Reinsurance & Monoline Excess segments. See our latest...

Glass House Brands (OTCPK:GLAS.F) has just posted a mixed FY 2025 picture, with Q3 revenue of US$38.4 million and a basic EPS loss of US$0.19, set against trailing 12 month revenue of US$196.2 million and a basic EPS loss of US$0.23. Over recent quarters, the company has seen revenue range from US$53.0 million in Q4 2024 to US$59.9 million in Q2 2025, while basic EPS has swung between a profit of US$0.10 in Q4 2024 and a loss of US$0.19 in Q3 2025. This keeps the focus firmly on how...

Oklo Inc. reported a full-year 2025 net loss of US$105.66 million, compared with US$73.62 million a year earlier, while basic loss per share from continuing operations narrowed slightly to US$0.72 from US$0.74. At the same time, Oklo secured a U.S. Department of Energy Other Transaction Agreement and key Nuclear Safety Design Agreement approvals that advance its first Aurora reactor and fuel fabrication facility at Idaho National Laboratory under the DOE’s Reactor and Fuel Line Pilot...

Vera Therapeutics (VERA) has been drawing attention after a long run of clinical development work in immunological kidney and viral diseases, prompting investors to reassess the stock’s recent performance and risk profile. See our latest analysis for Vera Therapeutics. Vera Therapeutics’ share price has cooled recently, with a 30 day share price return showing a decline of 4.52% and a 90 day share price return showing a decline of 27.86%, even though the 1 year total shareholder return is 55%...

Inspire Medical Systems (NYSE:INSP) has put forward a proposal to amend its Certificate of Incorporation. Shareholders are scheduled to vote on the amendment at the upcoming annual general meeting. The change targets the company’s core governance framework, which may influence how future decisions are approved and overseen. The vote comes at a time when Inspire Medical Systems shares trade around $51.41, with returns showing an 8.8% decline over the past week and 11.8% over the past month...

Recent commentary around Old Dominion Freight Line (ODFL) has focused on a 3.2% annual revenue decline over the past two years, falling earnings per share, and softer returns on capital that have started to worry some investors. See our latest analysis for Old Dominion Freight Line. Despite the softer fundamentals, the 90 day share price return of 18.59% and year to date share price return of 18.71% suggest momentum has picked up. However, the 1 year total shareholder return of 12.82% points...

Everest Group (EG) is back on investors’ radar after recent share price moves, with the stock last closing at $323.93 and showing mixed performance over the past month and past 3 months. See our latest analysis for Everest Group. The recent 7 day share price return of 1.27% comes after a softer 30 day share price return of 4.10% and a year to date share price return decline of 3.15%, while the 1 year total shareholder return decline of 9.36% contrasts with a 45.69% gain over five years. This...

SoFi Technologies (SOFI) is back in the spotlight after short seller Muddy Waters Research accused the company of improper accounting and unrecorded debt, claims SoFi strongly rejected while flagging potential legal action. See our latest analysis for SoFi Technologies. The short report and SoFi’s legal response come after a sharp 39.7% year to date share price decline and a 39.7% 3 month share price return, even though the 3 year total shareholder return is around 3x and the 1 year total...

In recent years, Phibro Animal Health has reported annual revenue growth of 21.7% alongside higher operating profits and efficiency, pointing to stronger execution in its animal health portfolio. This combination of faster sales expansion and better cost leverage suggests Phibro has been gaining share and improving how effectively it converts revenue into profit. Now we’ll examine how this improved operating performance may reshape Phibro Animal Health’s existing investment narrative and...

Geopolitical reprieve lifts Gates Industrial shares Postponed military action against Iran sparked a broad rebound in cyclical stocks. Gates Industrial (GTES) climbed 5.6% as investors showed renewed interest in companies tied to construction equipment and manufacturing. See our latest analysis for Gates Industrial. That rebound comes after a mixed stretch, with a 3.5% 7 day share price return and a 7.2% year to date share price return, set against a 14.8% 1 month decline. At the same time,...

Wondering whether Syndax Pharmaceuticals at US$24.20 is offering fair value or a potential gap between price and worth? This article walks through the key signals you should know before making up your mind. The stock has shown strong price swings recently, with returns of 2.3% over 7 days, 21.6% over 30 days, 13.6% year to date, and 84.3% over 1 year. This may reflect shifting views on both its opportunities and its risks. Recent coverage around Syndax Pharmaceuticals has focused on its...

Tokenized cash platform puts CME Group (CME) in focus CME Group (CME) is drawing fresh attention after partnering with Bank of Montreal and Google Cloud on a tokenized cash and deposit platform that enables 24/7 institutional settlement and collateral movements. See our latest analysis for CME Group. The recent tokenized cash announcement comes after a period of mixed momentum for CME Group, with a recent 1-day share price return of a 2.89% decline and a 7-day share price return of a 4.85%...

Omnicom Group overview Omnicom Group (OMC) has drawn investor attention after recent trading left the shares around $75.74, with returns negative over the past month, past 3 months, year to date, and past year. See our latest analysis for Omnicom Group. Recent trading reflects fading momentum, with a 30 day share price return showing a 6.20% decline and a 1 year total shareholder return showing a 2.98% decline, despite a positive 5 year total shareholder return of 21.77%. If you are weighing...

Wondering if Albemarle at a last close of US$181.39 still offers value, or if the best gains are already in the rearview mirror. The stock has returned 9.4% over the last 7 days, 2.2% over 30 days, 26.0% year to date, and 143.8% over the past year, while the 3 year and 5 year returns sit at negative 15.5% and 31.7% respectively. Those swings in performance set the scene for a closer look at what might be driving sentiment, from changing expectations around Albemarle's end markets to shifting...

In early 2026, Definium Therapeutics, formerly Mind Medicine, gained fresh attention after completing enrollment for its Phase III Emerge trial of DT120 in major depressive disorder and advancing toward multiple pivotal readouts in generalized anxiety and depression later in the year. This pipeline progress, alongside an early-stage program in autism spectrum disorder, is prompting investors to reassess how close Definium may be to shifting from pure R&D toward potential commercialization in...